絞り込み

16555

広告

温暖化でビール高値に 大麦の収穫減で - 毎日新聞

温暖化でビール高値に 大麦の収穫減で毎日新聞地球温暖化がこのまま進むと大麦の収穫量が減り、今世紀後半にはビールの値段が2倍以上になってしまうかも--。こんな予測...

  1. 温暖化でビール高値に - 徳島新聞
  2. 温暖化でビール高値に (デイリースポーツ...
  3. 温暖化でビール高値に 大麦の収穫減、今世...
  4. 温暖化でビール高値に 大麦の収穫減、今世...

ニュース一覧

スターを付ける スターを付ける     (50view , 0users)

Full Text Sources

Osteoporosis is the most widespread skeletal disease requiring innovative therapeutic strategies for its management. The understanding of receptor activator of nuclear factor kappa-B ligand (RANKL) and sclerostin's role in bone cell biology is completely changing the therapeutic landscape. RANKL supports osteoclast formation and activity and is mainly produced by cells of osteoblastic lineage. Sclerostin, an antagonist of the Wnt pathway, has a key role in bone formation and is mainly secreted by osteocytes. High levels of RANKL and sclerostin have been detected in osteoporosis, leading to the production of antibodies able to neutralize their activity. Areas covered: In this review, the authors give an overview and discuss the literature and data on denosumab and romosozumab to treat osteoporosis. Clinical studies indicate that long-term treatment with denosumab causes a continuous increase in bone mineral density with low incidence of adverse effects. Romosozumab treatment gives increases bone formation and improves bone mineral density (BMD) though further studies are needed to better evaluate the adverse effects. Expert opinion: Denosumab and romosozumab show promise in the treatment of osteoporosis. Furthermore, their different mechanisms of action compared to existing anti-osteoporotic drugs may permit alternative strategies for osteoporosis treatment down the line.
PMID: 29113523 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード